Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + Yervoy
nivolumab plus ipilimumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Nivolumab 360 mg every three weeks with ipilimumab 1 mg/kg every six weeks for the existing first-line metastatic NSCLC indication with PD-L1 at least 1% and no EGFR or ALK genomic aberrations.
LAMPGEN ANALYSIS
Why it matters
This action adds a fixed nivolumab schedule to the established dual-checkpoint regimen.
What research teams should watch
Coordinate the three- and six-week dosing intervals and distinguish this regimen from combinations with chemotherapy.
PRIMARY RECORDS